The US Centers for Disease Control and Prevention estimate that 1.7 million individuals sustain a traumatic brain injury (TBI) annually in the US 1 , comprising a serious health epidemic. The long-term neurological consequences of TBI include a host of emotional, cognitive and sensory deficits that can degrade quality of life, cause permanent disability or result in death. There currently is no pharmacological treatment for the neurological morbidities associated with TBI, and efforts to reduce the high incidence of TBI are primarily preventive.
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Animal models have been designed to parallel the pathological processes that occur in humans suffering from TBI 2 . These animal models are powerful tools for evaluating morbidities and for testing therapeutic interventions after injury. The consideration of animal welfare is vital when using research animals; pain and distress should be minimized through the use of anesthetic and analgesic agents. The introduction of anesthetics during experimental TBI, and the use of analgesics for post-traumatic pain management, can interfere with post-injury processes and functional outcomes, however. Here, we discuss how the use of anesthetic and analgesic compounds can interfere with the evaluation of functional and histopathological outcomes following experimental TBI.
ANIMAL MODELS OF TBI
Accurate models of TBI must replicate a complex pathological process characterized by two phases: primary injury, resulting from a mechanical force, and the ensuing secondary injury, mediated by the immune, circulatory and central nervous systems 3 . Federal research regulations 4,5 require researchers to first consider all reasonable alternatives to animal use that could adequately answer the proposed question before conducting studies with animals. Specific aspects of brain injury, such as cell death, have been successfully modeled with in vitro neural injury 6, 7 . But in vitro models cannot be sustained over time to evaluate injury progression, and they lack the complex interactions among systems that characterize TBI neuropathy. Current computer models also do not sufficiently reproduce the complicated pathophysiology of TBI and often only model mechanical 1 Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, AZ. 2 [1] [2] [3] Valid modeling of traumatic brain injury (TBI) requires accurate replication of both the mechanical forces that cause the primary injury and the conditions that lead to secondary injuries observed in human patients. The use of animals in TBI research is justified by the lack of in vitro or computer models that can sufficiently replicate the complex pathological processes involved. Measures to reduce nociception and distress must be implemented, but the administration of anesthetics and analgesics can influence TBI outcomes, threatening the validity of the research. In this review, the authors present evidence for the interference of anesthetics and analgesics in the natural course of brain injury in animal models of TBI. They suggest that drugs should be selected for or excluded from experimental TBI protocols on the basis of IACUCapproved experimental objectives in order to protect animal welfare and preserve the validity of TBI models.
forces related to the primary injury [8] [9] [10] . The complex neurovascular responses after TBI can be sufficiently modeled only in live animals. Therefore, the use of animal models in neurotrauma research has been deemed appropriate by neurotraumatologists 11 .
A range of experimental animal models of TBI has been developed, each using different biomechanical mechanisms of primary injury ( Table 1) . These mechanisms can be classified as causing either focal or diffuse injury. Each model can be used to evaluate post-traumatic morbidities and to test therapeutic interventions after TBI occurs. The majority of experimental brain injuries model mild to moderate TBI and do not result in coma. For this reason, rodents are rarely kept in drug-induced sedation or coma after injury. Braininjured animals can be maintained beyond 6 months after injury to evaluate chronic histopathological, behavioral and biochemical changes.
TBI is associated with acute and chronic pain, both in humans and in animal models: the initial trauma elicits somatic pain, and secondary injury mechanisms contribute to visceral and neuropathic pain 12, 13 . Measures to reduce nociception and distress must therefore be implemented before, during and after the induction of the primary injury. The use of anesthetics and analgesics, however, must be balanced against scientific objectives. Administration of anesthetics and analgesics can both positively and negatively influence post-injury processes and elicit functional changes in animal models of TBI ( Table 2) , interfering with the validity of outcome measures.
ANESTHETICS IN TBI RESEARCH Inhaled anesthetics
Anesthetics are routinely administered during the induction of experimental TBI to minimize pain and discomfort and to immobilize the animal. Anesthetics induce a variety of reversible effects, depending on the concentrations at which they are delivered 14 . At lower concentrations, inhaled anesthetics induce euphoria, amnesia and hyperreflexia, but as concentrations increase, anesthetics can lead to deep sedation and diminished somatic and autonomic responses to stimuli 14 . Anesthetic effects also vary depending on the agent used. Inhaled anesthetics target both the spinal cord and the brain with differing mechanisms of action. Within the brain, they depress blood flow and glucose metabolism, particularly in the thalamus and midbrain reticular formation 14 , to mediate amnesic effects. Most inhaled anesthetics alter receptor-mediated synaptic signaling and, consequently, synaptic transmission 15 . Anesthetic action on the spinal cord eliminates movement in response to painful stimuli, whereas action at supraspinal sites results in general anesthesia 14, 16, 17 .
Commonly used anesthetics provide varying degrees of neuroprotection, greatly altering post-injury outcome 18 . For example, isoflurane, an inhaled anesthetic commonly used in veterinary medicine, has been shown to improve behavioral outcome in the controlled cortical impact (CCI) model of TBI in rats, possibly through modulation of excitotoxicity or an increase of cerebral blood flow 19 . Rats anesthetized with isoflurane performed better on motor tests (e.g., beam balance, beam walking) and cognitive tests (e.g., Morris Water Maze) compared with rats anesthetized intravenously with fentanyl. Isoflurane also attenuated damage to the hippocampus, specifically to the CA1 region, when compared with fentanyl treatment.
A comprehensive study evaluated the effects of several anesthetics on cognitive outcome following CCI in rats and provided evidence that the choice of anesthetics in experimental TBI critically influences cognitive and physiological outcomes 20 . Isoflurane-treated rats (1% by inhalation) had improved latency times in the Morris Water Maze compared with rats treated with fentanyl (50 µg per kg body weight per h intravenously) or diazepam (3.4 mg per kg body weight intravenously). Examination of neuronal survival in the hippocampus following CCI using cresyl violet staining showed that the anesthetics protected against cell death to varying extents; isoflurane treatment offered the most neuroprotection, whereas ketamine treatment offered the least protection against cell death. The mechanisms underlying the neuroprotective effects of isoflurane may include modulation of excitotoxicity via attenuation of glutamate release 21 as well as blockade of NMDA receptors 20, 22 .
Although preconditioning with isoflurane has been shown to prevent some of the harmful effects of TBI in animal models [18] [19] [20] 23 , isoflurane general anesthesia may negatively influence neurological outcome in a rat CCI model of TBI 24 . Rats preconditioned with higher concentrations of isoflurane had greater cortical damage, assessed by apoptotic cell markers, and a worse cognitive outcome, measured by a standardized inclined plane test, than rats preconditioned with lower concentrations of isoflurane.
TBI initiates a cascade of secondary injury processes that contributes to the outcome of the injury. Administration of anesthetics shortly after experimental TBI can act on these secondary injury mechanisms to mitigate damage. For example, isoflurane given after a modified weight drop injury may protect against lipid peroxidation, a secondary injury mechanism characteristic of TBI 25 .
Administration of anesthetics can affect normal ventilation and carbon dioxide levels, which consequently alter intracranial pressure, cerebral perfusion pressure and cerebral blood flow [26] [27] [28] . Sevoflurane, a general inhalational anesthetic, raised intracranial pressure when given after diffuse impact acceleration brain injury in rats 29 . Sevoflurane also caused a more pronounced decrease in cerebral perfusion pressure than isoflurane, possibly owing to the difference in cerebrovasodilatatory effects of each anesthetic 29 .
Injectable anesthetics
Propofol is a general injectable anesthetic that, like isoflurane, modulates GABA receptors 30, 31 . Propofol used in combination with moderate hypothermia significantly lowered intracranial pressure and significantly raised cerebral perfusion pressure, when compared with isoflurane combined with hypothermia, in rats subjected to diffuse impact acceleration injury 30 . In another study, the administration of propofol prior to weight drop injury in rats was found to be neuroprotective, altering the synthesis of nitric oxide and ultimately reducing lipid peroxidation 32 .
Anesthetic compounds that act as antagonists at the N-methyl-D-aspartate (NMDA) receptor may also have neuroprotective properties [33] [34] [35] , improving outcome from TBI 36 . Rats subjected to fluid percussion injury (FPI) and administered ketamine, an injectable non-competitive NMDA receptor antagonist, showed preserved memory function 36 . Intraperitoneal injections of ketamine given to rats before CCI did not prevent TBI-induced intracerebral cytokine production and had minimal effect on the early local inflammatory response 37 , suggesting that ketamine alters the course of brain injury through mechanisms other than inhibition of inflammation.
ANALGESICS IN TBI RESEARCH
Ethical standards to protect the well-being of animals used for biomedical research include proper pain management following surgical procedures. Post-surgical analgesics have been shown to be neuroprotective, confounding the evaluation of post-injury outcome measures 38, 39 . Furthermore, comprehensive dosing paradigms of common analgesic drugs have not been determined in all experimental TBI models. It is also not well known to what degree these drugs may interfere with molecular, functional and behavioral outcomes. For these reasons, analgesics must be carefully considered and tested before being administered in experimental TBI in order to maintain a valid and reproducible animal model.
COX inhibitors
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly administered to mitigate inflammation and accompanying pain. During the inflammatory process, cyclooxygenase (COX) enzymes facilitate the conversion of arachidonic acid into inflammation-mediating prostaglandins 40, 41 . NSAIDs reduce prostaglandin synthesis by inhibiting the production of COX-1 and COX-2 (ref. 42 ). Administration of carprofen, an NSAID, to mice after weight drop injury resulted in a more rapid and pronounced improvement of neurological deficits, as measured by the Neurological Severity Score, compared with administration of vehicle alone 43 . In contrast, chronic NSAID administration following TBI can lead to worsened outcomes 44 . Ibuprofen administered chronically over a 4-month period to rats subjected to FPI led to a decline in cognitive function, as measured by the Morris Water Maze.
Specific COX-2 inhibitors are also effective in suppressing inflammation, a secondary injury mechanism. Rats that received nimesulide, a COX-2 inhibitor, after impact acceleration-induced diffuse TBI showed improvement in functional and motor deficits over the post-injury assessment period in comparison with vehicle-treated controls 45 . Treatment with nimesulide improved mean escape latencies using the Barnes circular maze to assess spatial reference memory and attenuated motor deficits measured using the rotarod test. Another study showed that 5,5-dimethyl-3(3-fluorophenyl)-4 (4-methylsulfonyl)phenyl-2(5H)-furanone (DFU), a selective COX-2 inhibitor, improved neurological reflexes and memory, as compared with a vehicle control, when administered following cortical impact in the rat 46 .
Administration of analgesics alters not only functional outcome but also cellular mechanisms following experimental TBI. Weight drop-injured mice treated with carprofen had a significant decrease in lesion size post-injury and increases in cell proliferation and gliogenesis in comparison with vehicle-treated controls 43 . The administration of other analgesics, such as nimesulide, has been shown to alter cellular mechanisms in rats following an impact accelerationinduced TBI 45 . Rats in this model typically exhibited a marked increase in COX-2 protein expression in the hippocampus, but nimesulide attenuated this increase 45 . Administration of DFU following CCI in the rat attenuated the amount and intensity of COX-2 immunoreactivity in the cortex, as compared with administration of vehicle only, and decreased the number of activated caspase-3-immunoreactive cells in both the injured cortex and hippocampus 46 .
Opioids
Endogenous and administered opioids attenuate responses to many painful stimuli in both humans and animals. TBI stimulates the release of endogenous opioid receptor agonists, which contribute to the secondary injury cascade [47] [48] [49] . Mice treated with morphine immediately post-injury were protected from the long-term, but not short-term, cognitive deficits that result from TBI, as measured by the Morris Water Maze task 47 . Morphine has also been shown to reduce behavioral deficits when given to rats just prior to FPI [50] [51] [52] . Morphine given in combination with scopolamine, a muscarinic receptor antagonist, provided even greater protection of motor function 51 .
CONCLUSIONS
Valid modeling of TBI in animals requires accurate replication of both the mechanical forces and secondary injury conditions experienced by human patients. Our review indicates that the administration of anesthetics at the time of or shortly after injury, and the administration of analgesics to control perioperative pain, alter the outcome of TBI. Regardless, investigators are obligated to minimize animal pain and distress in their research protocols, and pain management remains of utmost concern. The interference of anesthetics and analgesics in the natural course of brain injury calls for special consideration of pain management drugs when using animal models of TBI.
The privilege of using animals in research demands a high level of responsibility. Withholding of anesthetics, analgesics or tranquilizers must be scientifically justified by investigators and subsequently approved by an institutional animal care and use committee (IACUC). Studies in which animals are subjected to painful or stressful conditions without the use of anesthetics, analgesics or tranquilizers are classified by the USDA and Animal Welfare Act as Category E 4, 5 . Category E studies must show that less painful or stressful alternatives are not available or that less painful or stressful endpoints cannot be reasonably substituted. Because human TBI often occurs in the absence of anesthetics and analgesics, which can confound outcomes, studies using in vivo models of TBI may be classified as Category E procedures in which drugs can be withheld. Anesthetics should not be completely avoided, however. Instead, pain management strategies should be selected on the basis of experimental objectives for each study in light of the potential confounds on assessment outcomes and in accordance with local and federal regulations.
Because of the variability among TBI models and experimental outcome measures, uniform recommendations for anesthesia and analgesia are not practical. For this reason, recommendations for specific drug choice and dosing were not included in this review. The use of anesthetics in TBI models should be standardized within studies, however, to provide consistency in drug type, timing and dosage. This will help to alleviate confounding factors that may influence postinjury outcome measures and will also permit crossstudy comparison of results. Investigators are urged to establish a standard of animal care specific to individual experimental objectives based on pilot study data.
